This advanced data system is intended to be employed in BTI’s recently initiated exploratory and adaptive multicenter clinical study of BTI320 in type 2 diabetes patients.
This platform we believe will provide Boston Therapeutics with considerable value by cost effectively achieving the highest quality data and outcomes assessment in the shortest possible time frame.
Prevail Partners, an investment fund, may allocate an investment of up to $500,000 by a stock purchases at a 25% premium to market price as part of the pending additional contracts for services.
Boston Therapeutics CEO Carl Rausch said: “It is a mitigation of risk and great support of outcome clarity that is a strength of the Prevail InfoWorks technology services. This industry leading analytics driven process and data management company is precisely what is needed to drive an efficient and effective regulatory pathway to FDA approval.”
Prevail Partners president Mary Schaheen said: “Everyone here is confident in the growth and success of Boston Therapeutics as they develop BTI320. Furthermore, Boston Therapeutics has a seasoned management team with the expertise to accelerate to a significant value inflection point through the completion of its planned clinical trials.”
This strategic partnership is built upon important analytics of the new CGM technology. Prevail InfoWorks offers cost-competitive services for which Boston Therapeutics will find a significant value-add in terms of unique capabilities, and Prevail Partners participates as the company achieves product development milestones.
Source: Company Press Release
